MedTrace Logo

Unbound Cloxacillin Concentrations During Continuous Infusion

NCT06848387 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-02-17

No results posted yet for this study

Summary

Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.

Conditions

  • Staphylococcal Infections

Interventions

DIAGNOSTIC_TEST

Unbound cloxacillin concentration

Unbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.

Sponsors & Collaborators

  • Region Västmanland

    collaborator OTHER

  • Emeli Månsson

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-14
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06848387 on ClinicalTrials.gov